MedTrace Logo

Predictive Value of NT-proBNP on MACEs After Acute Coronary Syndrome

NCT06569511 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 241

Last updated 2024-08-26

No results posted yet for this study

Summary

The role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) as a cardiac biomarker in predicting short-term major adverse cardiovascular events (MACEs) in patients with Acute coronary syndrome (ACS) has been insufficiently reported and remains poorly understood. Additionally, the relationship between NT-proBNP levels and specific ACS subtypes has not been thoroughly examined. Therefore, our study investigated the predictive value of high-sensitivity cardiac troponin (hs-cTn) and NT-proBNP levels on admission for 6-month MACEs in patients who presented to the emergency department (ED) with ACS and subsequently underwent percutaneous coronary intervention (PCI). Furthermore, we sought to evaluate the association between MACEs and specific ACS subtypes.

Conditions

  • Acute Coronary Syndrome
  • ST-segment Elevation Myocardial Infarction (STEMI)
  • Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)
  • Major Adverse Cardiac Events

Interventions

DIAGNOSTIC_TEST

N-terminal pro-B-type natriuretic peptide (NT-proBNP)

In patients diagnosed with Acute coronary syndrome, blood samples for serum NT-proBNP value were taken during transfer to the coronary intensive care unit

DIAGNOSTIC_TEST

high sensitive cardiac troponin T (hs-cTnT)

In patients diagnosed with Acute coronary syndrome, serum high-sensitive cardiac troponin T (hs-cTnT) levels were measured on admission to the Emergency Department.

Sponsors & Collaborators

  • Haseki Training and Research Hospital

    lead OTHER

Principal Investigators

  • Adem Az, M.D. · Haseki Training and Research Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2024-02-01
Completion
2024-03-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06569511 on ClinicalTrials.gov